Meeting Banner
Abstract #0126

Chemotherapeutic drugs profoundly alter the metabolism of triple negative breast cancer cells

Kanchan Sonkar1, Caitlin M. Tressler1, and Kristine Glunde1,2
1The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States, 2The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, United States

Triple negative breast cancer (TNBC) is a highly aggressive form of cancer that poses severe health care problem as no targeted therapeutics are available for its treatment. TNBC is treated with chemotherapeutic agents, including doxorubicin, paclitaxel, vinorelbine, 5-fluorouracil, melphalan and cisplatin , which are either used alone or in various combinations. Studies investigating the metabolic effects of chemotherapy in TNBC are still limited. Here we have used high-resolution 1H MRS to study the metabolic profiles of TNBC cell lines MDA-MB-231 and SUM159 treated with these chemotherapeutic agents as compared to untreated controls.

This abstract and the presentation materials are available to 2020 meeting attendees and eLibrary customers only; a login is required.

Join Here